# David Atkinson

> David Atkinson is a pre-seed investor at Tate & Lyle Ventures backing Biotechnology and Nutrition. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Tate & Lyle Ventures](https://shizune.co/investors/profile/tate-lyle-ventures)
- Location: London, United Kingdom
- Total investments: 5
- Last investment: Dec 2022
- Lead investor: 40%
- Last updated: Aug 2026
- LinkedIn: http://uk.linkedin.com/pub/david-atkinson/3/506/baa

David Atkinson is a pre-seed investor at Tate & Lyle Ventures in London focused on Biotechnology and Nutrition. David Atkinson having held a number of senior management positions in the City brings a background in investment banking with a close association with the food industry to the team. He currently serves as a director of BioFilm Holdings Ltd. (UK), Fugeia NV (Belgium) and Lumora Ltd. (UK).David spent over 14 years in equity research specificallyfocused on the food processing industry. David worked at SG Warburg Securities before joining NatWest Securities to head up the pan-European Food Producers research team. During his time in charge the team was consistently top-three ranked in the Extel and Institutional Investor buy-side surveys. David was appointed Managing Director and Head of European Research at NatWest Securities in 1996 and was a member of the Equities Management Committee. In 1998, David co-founded Stamford Partners, one of the leading investment banking firms providing merger and acquisition and strategic consulting services to the European food industry, where he further developed his extensive food industry network. David has also held several senior management positions in the equities operations of Banc of America Securities as well as providing consultancy services to HSBC and the VC industry.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 40% |
| Nutrition | 1 | 20% |
| Blockchain | 1 | 20% |
| Social Impact | 1 | 20% |
| Web Development | 1 | 20% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Pre-Seed | 1 | 20% |
| Series A | 1 | 20% |
| Series B | 1 | 20% |
| Funding Round | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 1 | 20% |
| United Kingdom | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Dapps | Dapps make it simple for web3 applications to integrate and communicate with one another on the blockchain, enabling you to easily attain the highest level of discoverability within and outside of the community. |  | Pre-Seed | Dec 23, 2022 |  |
| Nutriati | Nutriati is a food technology company focused on the research, development and commercialization of innovative plant-based food ingredients. It is dedicated to formulating nutritious food products that are widely attractive to a broad range of consumer tastes. The company's business strategy includes a commitment to positive social impactand the promotion and distribution of healthier component ingredients in the food supply, resulting in improved health and well-being globally.Nutriati was founded in 2013 and is headquartered in Richmond, Virginia, United States. | $8M | Series A | Apr 21, 2017 |  |
| Lumora | Lumora Ltd, a Cambridgeshire Business Park, UK-based molecular diagnostics company. The company intends to use the funds to accelerate its entry into the clinical molecular diagnostic market. Based on its proprietary BART Technology platform, Lumora is developing programs focusing on:- an integrated testing station for gastrointestinal (GI)infections, and- an HIV viral load monitoring system to support drug therapy in the developing world. | $917K |  | Mar 19, 2013 |  |
| Lumora | Lumora Ltd, a Cambridgeshire Business Park, UK-based molecular diagnostics company. The company intends to use the funds to accelerate its entry into the clinical molecular diagnostic market. Based on its proprietary BART Technology platform, Lumora is developing programs focusing on:- an integrated testing station for gastrointestinal (GI)infections, and- an HIV viral load monitoring system to support drug therapy in the developing world. | $2M | Series B | May 26, 2011 |  |
| Lumora | Lumora Ltd, a Cambridgeshire Business Park, UK-based molecular diagnostics company. The company intends to use the funds to accelerate its entry into the clinical molecular diagnostic market. Based on its proprietary BART Technology platform, Lumora is developing programs focusing on:- an integrated testing station for gastrointestinal (GI)infections, and- an HIV viral load monitoring system to support drug therapy in the developing world. |  |  |  |  |

5 of 5 investments shown.

## Co-investors
- [Catapult Ventures](https://shizune.co/investors/profile/catapult-venture-managers) — VC Fund, 2 deals together
- [Blueberry Ventures](https://shizune.co/investors/profile/blueberryventures) — VC Fund, 1 deal together
- [NRV](https://shizune.co/investors/profile/new-richmond-ventures) — VC Fund, 1 deal together
- [GroundForce Capital](https://shizune.co/investors/profile/powerplant-ventures) — VC Fund, 1 deal together

## About Tate & Lyle Ventures

VC Fund · London, United Kingdom

Tate & Lyle Ventures is a £25M venture capital fund focused on investing in high growth companies in the fields of renewable ingredients, food technologies, biomaterials and industrial processing technologies. Their cornerstone investor is Tate & Lyle PLC, one of the world's leading renewable ingredients companies focused oninnovation and product development in these sectors.They are proactive investors investing practically as well as financially by supporting the management teams they back with experience, strategy and networks. They prefer to work as lead investors but occasionally work as syndicate members alongside other investors such as business angels, venture capital funds and corporate investors.They can invest in businesses around the world. They invest in technology-based businesses across food science and technology. They generally make an initial investment of £1-2M followed by further amounts of follow-on investment. They consider smaller investments and seed deals when the business is on a very steep growth curve leading to greater capital requirements.

2 contacts available at Tate & Lyle Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| David Atkinson | Managing Partner | https://shizune.co/investors/profile/david-atkinson-2 |
| Simon Barnes | Managing Partner | https://shizune.co/investors/profile/simon-barnes-2 |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Everywhere Ventures](https://shizune.co/investors/profile/everywhere-ventures) — VC Fund

## FAQ

### What does David Atkinson invest in?

David Atkinson invests primarily in Biotechnology, Nutrition and Blockchain startups, most often at Pre-Seed and Series A stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did David Atkinson last invest?

The most recent investment recorded for David Atkinson closed in Dec 2022. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co